《復牌公告》東陽光長江藥業(01558.HK)母企擬以介紹形式上主板 研以換股方式與公司合併
東陽光長江藥業(01558.HK)公佈,瞭解到母公司廣東東陽光藥業正考慮以換股方式將公司吸收合併,並將以介紹形式在聯交所主板上市的新H股作爲註銷價。待可能合併完成後,公司在聯交所的上市地位將會被取消。可能合併及可能上市仍處於初步階段,且難以確定會否進行。
此外,直接股東香港東陽光向廣東東陽光藥業轉讓25.71%持股,總對價20.67億元,相較於每股作價9.14元,較停牌前收報折讓18.68%。
公司股份已申請週一(11日)恢復買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.